Ocular.D
Ocular.D eye drops relieve symptoms of digital eye strain caused by screen use.

BioLight Life Sciences is an Israeli company that invests solely in ophthalmology.
bio-light.co.ilCrawled Nov 18, 2026
Ocular.D eye drops relieve symptoms of digital eye strain caused by screen use.
DiagnosTear develops diagnostic solutions for eye diseases using its TeaRx platform, which analyzes tear fluid for point-of-care testing.
LipiCare Pharmaceuticals develops nano-emulsion eye solutions using phospholipids to deliver fatty medications effectively to the eye.
Ocuvia Ocuvia is a planned merger of Visci and Ophrx Ocuvia Presentation
OphRx develops drugs for eye diseases using a nanostructure-based platform, initially focusing on high-dose cyclosporine.
ViSci’s Eye-D technology treats glaucoma with a sub-conjunctival implant (VS-101) that releases latanaprost, eliminating the need for daily eye drops.
Investor Relations Innovation in ophthalmology in Israel 04/05/2021 read more 03/08/2021 read more
Investor Relations Press Releases 09/21/2023 read more 05/29/2023 read more 07/28/2022 read more 03/24/2022 read more 02/07/2022 read more
BioLight Life Sciences Ltd. focuses exclusively on ophthalmology, investing in medical devices, medications, diagnostics, and digital healthcare.
BioLight Life Sciences Ltd. advances ophthalmology through medical devices, diagnostics, and drug delivery technologies, including DiagnosTear’s TeaRx and ViSci’s VS-101.
BioLight Life Sciences Ltd. provides accessible and professional service on its website to accommodate users with disabilities.
DiagnosTear Technologies raises capital through a private placement of units to support its TeaRx point-of-care diagnostic development pipeline. The company advances its diagnostic tools designed for immediate clinical use. Funding will support ongoing research and product refinement in its specialized diagnostic portfolio.
Diagnostear, a subsidiary of BioLight Life Sciences Ltd, has entered into a binding Letter of Intent for a merger with a Canadian corporation. The deal includes plans for a capital raise and listing on the Canadian Securities Exchange (CSE). BioLight, a publicly traded company on the Tel Aviv Stock Exchange, specializes in investments in biomedical firms focused on eye diseases.
BioLight partners with Alexion to investigate a tear-based diagnostic technology for retinal diseases. The collaboration focuses on a novel approach using natural tears to potentially identify conditions affecting the retina. Both companies aim to advance early detection methods in ocular health.
BioLight partners with Alexion (AstraZeneca Rare Disease) to develop a diagnostic technology using natural tears for identifying retinal diseases. The collaboration focuses on an innovative approach to detect biomarkers in tears, aiming to improve early diagnosis methods. Both companies will jointly explore the feasibility and potential applications of this technology in clinical settings.
BioLight announces positive results from its second clinical study of the TeaRx™ multi-assay test, designed to diagnose dry eye syndrome. The test evaluates multiple biomarkers to improve diagnostic accuracy. The company’s proprietary platform aims to address unmet clinical needs in ophthalmology by providing objective, data-driven assessments.
BioLight secures a U.S. patent for its long-term controlled-release drug-delivery insert platform. The innovation enables sustained medication release, potentially improving treatment adherence and efficacy for chronic conditions. The patent covers a novel insert-based system designed for extended therapeutic delivery.
BioLight’s subsidiary ViSci files an Investigational New Drug (IND) application with the FDA to begin a Phase I/IIa clinical trial of its subconjunctival, controlled-release Latanoprost insert for glaucoma treatment. The device aims to provide a novel, sustained-delivery approach for managing intraocular pressure. ViSci, a wholly owned subsidiary of BioLight, develops biomedical innovations in ophthalmology.